Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ketamine Infusion Therapy for PTSD in Combat Veterans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03088384
Recruitment Status : Completed
First Posted : March 23, 2017
Last Update Posted : October 2, 2018
Information provided by (Responsible Party):
Klarisana Physician Services PLLC

Brief Summary:
Klarisana is conducting an observational study in San Antonio, Texas to see if there are tangible improvements in the symptoms of post traumatic stress disorder (PTSD) in combat veterans after receiving a series of six low-dose outpatient infusions of ketamine.

Condition or disease Intervention/treatment
Stress Disorders, Post-Traumatic Drug: Ketamine

Detailed Description:

The prolonged conflicts in Iraq and Afghanistan have created a very large population of veterans who suffer from severe post traumatic stress disorder (PTSD). This has, in part, contributed to a rate of suicide that many clinicians and concerned citizens find alarming. In the last two decades, there has been some promising evidence coming to light showing that the medication ketamine can potentially suppress and/or alleviate some of the disturbing symptoms of PTSD such as hypervigilance, anxiety, anger, and recurrent nightmares. If ketamine could be shown to be be a valuable treatment option for PTSD then this could have potentially large positive ramifications for the treatment of PTSD in America's veteran population.

Ketamine has historically been used as a dissociative anesthetic in emergency departments, operating rooms, and in austere military environments. It is a proven medication with a reassuring safety profile. This current study seeks to add to the body of knowledge regarding ketamine therapy by specifically looking at the combat veteran population. Eligible veterans will undergo the standard six-infusion Induction Series of ketamine infusions at Klarisana in San Antonio, Texas. Klarisana is a healthcare center which offers outpatient ketamine infusion therapy for the treatment of severe depression, PTSD, and various chronic pain conditions such as rheumatoid arthritis, fibromyalgia, neuropathy, and migraine headaches. Klarisana serves patients from all over south Texas including Austin, Houston, San Antonio, and Corpus Christi.

Patients who enroll in the current PTSD study will receive a standard battery of survey instruments which Klarisana implements before and after a series of infusions. These instruments will assess each patient's level of depression, degree of PTSD symptoms, as well as their use of alcohol and recreational drugs. The specific instruments are the...

Patient Health Questionnaire (PHQ-9) PTSD Checklist (PCL-5) Drug Abuse Screening Test (DAST-10) Alcohol Use Disorders Identification Test (AUDIT)

The investigator's goal is to formally analyze what changes may occur the participants' symptoms of PTSD and try to better establish the role which ketamine infusion therapy may play in the treatment of PTSD in the combat veteran population.

Layout table for study information
Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans
Actual Study Start Date : November 28, 2016
Actual Primary Completion Date : September 27, 2018
Actual Study Completion Date : September 29, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Ketamine

Group/Cohort Intervention/treatment
Combat Veterans
Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
Drug: Ketamine
Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.

Primary Outcome Measures :
  1. Participant score on the PTSD Checklist - 5 (PCL-5) after a series of six ketamine infusions. [ Time Frame: 3 weeks ]
    The PCL-5 is a twenty question survey instrument which is used to quantify the level of symptomatology in participants with post-traumatic stress disorder.

Secondary Outcome Measures :
  1. Participant score on the Patient Health Questionnaire - 9 (PHQ-9) after a series of six ketamine infusions. [ Time Frame: 3 weeks ]
    The PHQ-9 is a nine-question survey instrument which is used to quantify the level of depressive symptoms in participants.

  2. Participant score on the Drug Abuse Screening Test (DAST-10) after a series of six ketamine infusions. [ Time Frame: 3 weeks ]
    The DAST-10 is a ten-question self-report survey instrument which is used to assess participants' use of illicit drugs.

  3. Participant score on the Alcohol Use Disorders Identification Test (AUDIT) after a series of six ketamine infusions. [ Time Frame: 3 weeks ]
    The AUDIT is a ten-question self-reporting survey instrument which is used to identify participants' use of and potential dependence on alcohol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Veterans of the United States or foreign militaries who have served in combat and who now suffer from post traumatic stress disorder as a result of that military service.

Inclusion Criteria:

  • The Veteran must be medically screened by Klarisana and be an appropriate candidate for ketamine therapy
  • The Veteran must be between the ages of 18 and 75. The study is open to men and women.
  • The Veteran must be able to speak and read the English language
  • The Veteran must have a diagnosis of post-traumatic stress disorder assigned by the Department of Veterans Affairs. Veterans of a foreign military are also eligible but they must have been diagnosed with PTSD by the equivalent veteran healthcare organization in their country of military service
  • The Veteran must have served in the US Military or a foreign military service in a designated combat zone. Documentation by a DD214 or equivalent is required
  • The PTSD that The Veteran is suffering from has to have been caused by service in combat
  • The PTSD that the Veteran is suffering from must be exerting a significant negative effect on his/her life

Exclusion Criteria:

  • The Veteran must NOT be taking lamotrigine (Lamictal) or any monoamine oxidase inhibitor antidepressants
  • The Veteran must not be currently enrolled in any other studies offering therapy for PTSD
  • Veteran may NOT have uncontrolled blood pressure or congestive heart failure
  • Veteran may NOT have a diagnosis of psychosis or any diagnosis on the psychosis spectrum

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03088384

Layout table for location information
United States, Texas
San Antonio, Texas, United States, 78240
Sponsors and Collaborators
Klarisana Physician Services PLLC
Additional Information:

Layout table for additonal information
Responsible Party: Klarisana Physician Services PLLC Identifier: NCT03088384    
Other Study ID Numbers: KRP001
First Posted: March 23, 2017    Key Record Dates
Last Update Posted: October 2, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Klarisana Physician Services PLLC:
Post Traumatic Stress Disorder
Combat Trauma
Additional relevant MeSH terms:
Layout table for MeSH terms
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders
Mental Disorders
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action